Denali Therapeutics (DNLI)
NASDAQ:DNLI
Want to see DNLI full AI Analyst Report?
DNLI Stock Chart & Stats
$20.57
$0.28(1.32%)
At close: 4:00 PM EST
$20.57
$0.28(1.32%)
Day’s Range― - ―
52-Week Range$12.58 - $23.77
Previous CloseN/A
Volume399.31K
Average Volume (3M)1.89M
Market Cap
$3.44B
Enterprise Value$2.99B
Total Cash (Recent Filing)$987.68M
Total Debt (Recent Filing)$40.05M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Jul 30, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding158,709,730
10 Day Avg. Volume1,880,023
30 Day Avg. Volume1,890,350
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)2.86
Price to Sales (P/S)0.00
P/FCF Ratio-6.86
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-523.84
Enterprise Value/Ebitda-6.06
Forecast
1Y Price Target
$36.11Price Target Upside75.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.46
Revenue Forecast (FY)$42.49M
Bulls Say, Bears Say
Bulls Say
FDA Approval & Platform ValidationAccelerated approval of AVLAYAH is a durable commercial and scientific validation of Denali’s TransportVehicle BBB platform. It creates a pathway for recurring revenue from a first-in-class product, strengthens regulatory credibility, and can catalyze future collaborations and faster development for other brain-penetrant candidates.
Non-dilutive $200M Royalty FundingThe $200M royalty financing provides immediate non-dilutive liquidity that extends runway for commercialization and confirmatory trials. This durable capital alleviates near-term funding pressure, reduces necessity for equity raises, and supports execution of long-term clinical and commercial milestones.
Regained DNL593 Rights & Proprietary IPRegaining full rights to DNL593 and owning the TransportVehicle IP increases strategic optionality and potential future upside. Control of development and commercialization choices preserves value capture, enables streamlined decision-making, and strengthens long-term competitive positioning in BBB-delivery therapeutics.
Bears Say
High Cash Burn & Negative Operating Cash FlowSustained multi-hundred-million dollar negative operating cash flow is a persistent structural risk. Continued cash burn will necessitate additional financing or partnerships, gradually eroding equity if repeated, constraining R&D flexibility and potentially forcing slower program progression absent new revenue sources.
No Recurring Revenue (zero In 2024–2025 And TTM)The absence of recurring product revenue shifts financial reliance to one-time collaboration payments and milestone timing. Until AVLAYAH commercialization generates sustainable sales, revenue volatility increases funding uncertainty and makes long-term planning and investment in multiple programs more dependent on external capital events.
Major Clinical Setback In Parkinson’s ProgramHalting a large Phase 2b trial narrows near-term pipeline and undermines partner-backed development optionality. It signals elevated scientific risk in disease-modifying neurology programs, potentially reducing partner confidence, reprioritizing R&D spend, and lowering the likelihood of near-term revenue from that indication.
Denali Therapeutics News
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $12.58 and its highest was $23.77 in the past 12 months.
What is Denali Therapeutics’s market cap?
Denali Therapeutics’s market cap is $3.44B.
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 45 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on May 07, 2026. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.723 by $0.033.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -0.58.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 158,709,730 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.723. Following the earnings report the stock price went down -0.457%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Currently, no hedge funds are holding shares in DNLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Denali Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.11 (75.55% Upside)
$36.11 (75.55% Upside)
Blogger Sentiment
Bullish
DNLI Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 27.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.12%
12-Months-Change
Fundamentals
Return on Equity
-52.20%
Trailing 12-Months
Asset Growth
-0.42%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
DNLI Stock 12 Month Forecast
Average Price Target
$36.11
▲(75.55% Upside)
Technical Analysis
Agios Pharma
―
Celcuity
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Ownership Overview
5.34% Insiders
23.98% Mutual Funds
40.65% Other Institutional Investors
13.30% Public Companies and
Individual Investors